Profile #1104
Profile #1104 - Medical University of Lodz - Poland
Date: 2006/10/27
Deadline: 2009/11/03
Contact
Organisation
Medical University of Lodz
Contact
person
Mirowski, Professor Marek
Email
mirowski@ich.pharm.am.lodz.pl
Address
1 Muszynskiego Street
Postcode
90-151
Country
Poland
Telephone
48 22 6779130
Department
Molecular Biology and
Pharmacogenomics
Laboratory, Deparment of
Pharmaceutical Biochemistry
City
Lodz
Fax
48 22 6779130
Website
Organisation
Type:
Research Organisation & Universities
Is a Small and Medium Sized Enterprise (SME)? NO
Number of
Employees
4
Description of
research
activity:
The research activity of Molecular Biology and Pharmacogenomics Laboratory
focuses on a selctedgenes/proteins expression analysis in human neoplasms, e.g.
P65, HMGA1, CCND1, c-ErbB2, DD3, NIS. The main problem is estimation of
usefulness of P65 gene/protein expression as a tool in cancer dignosis and therapy.
Presently, our goal is to established P65 gene sequence and its chromosomal
localization.
The another problem is to investigate single nucleotide polymorphism of genes
encoding multidrug resistance proteins e.g. MDR1, BCRP, MRP and anticancer drug
metabolizing enzymes e.g. CYP3A4, CYP3A5, GSTP and NR3C1.
We are using such techniques as: reverse transcriptase-PCR, PCR, multiplex-PCR,
real-time PCR, PCR-RFLP, DNA sequencing, gel electrophoresis, immunoassays and
Western blot analysis.
Selected publications:
1. Niewiadomska H., Mirowski M., Stempien M., Olborski B., Błoński
J.Z., Hanausek M., Wierzbicki R. A 65 kDa oncofetal protein (P65), proliferating cell
nuclear antigen (PCNA) and Ki 67 expression in breast cancer patients.
Neoplasma 45, 4, 1998.
2. Niewiadomska H, Mirowski M, Stempień M, Błoński J,
Czyż W, Świtalska J, Matyga E (obecnie Balcerczak E), Hanausek M.,
Wierzbicki R. Immunohistochemical analysis of expression of a 65 kDa oncofetal
protein (P65), epidermal growth factor receptor (EGFR), oncogene c-erbB2 and
tumor suppressor gene p53 protein products in breast cancer patients. Neoplasma 1,
8-14, 2000
3. Niewiadomska H., Mirowski M., Kulczycka D., Najder M., Balcerczak E.
Błoński J. Some oncogene and tumor suppressor gene protein products
expression in B-cell chronic lymphocytic leukemia. Cytobios 103, 159-168, 2000.
4. Garnuszek P., Licińska I., Skierski JS., Koronkiewicz M., Mirowski M.,
Wiercioch R., Mazurek AP. Biological investigation of the platinum(II)[*I]iodohistamine complexes of potential synergistic anti-cancer activity. Nucl. Med.
Biol. 29(2), 57-63, 2002
5. Balcerczak E., Bartkowiak J., Błoński JZ., Robak T., Mirowski M.
Expression of gene encoding P65 oncofetal protein in acute and chronic leukemias.
Neoplasma 49, 295-299, 2002
6. Jamroziak K., Balcerczak E., Młynarski W., Mirowski M., Robak T.
Distribution of allelic variants of functional C3435T polymorphism of drug transporter
MDR1 gene in polish population. Pol J Pharmacol 54, 495-500, 2002
7. Czyż W., Balcerczak E., Rudowicz M., Niewiadomska H., Pasieka Z., Kuzdak
K., Mirowski M. c – erbB2 and p65 genes and their protein products expression in
follicular neoplasms of thyroid gland. Folia Histochemica et Cytobiologica 41(2), 3337, 2003
8. Balcerczak E., Mirowski M., Jesionek-Kupnicka D., Bartkowiak J., Kubiak R.,
Wierzbicki R. p65 and c-erbB2 genes expression in breast tumors: comparison with
some histological typing, grading and clinical staging. J Exp & Clin Cancer Res 22(2),
421-427, 2003
9. Mirowski M., Wiercioch R., Świtalska J., Byszewska E., Niewiadomska H.,
Michalska M. Uptake of radiolabeled alpha-fetoprotein (AFP) by experimental
mammary carcinomas and adenomas: in vivo and in vitro studies. Nucl. Med.
Commun. 24, 297-303, 2003
10. Balcerczak E., Mirowski M., Sasor A., Wierzbicki R. p65, DD3 and c-erbB2 genes
expression in prostate cancers. Neoplasma 50(2), 97-101, 2003
11. Mirowski M., Różalski M., Krajewska U., Balcerczak E., Młynarski
W., Wierzbicki R. Induction of caspase 3 and modulation of some apoptotic genes in
human acute promyelocytic leukemia HL-60 cells by carboplatin with amifostine. Pol
J Pharmacol 55, 227-234, 2003
12. Balcerczk M., Pasz-Walczak G., Balcerczak E., Wojtylak M., Kordek R., Mirowski
M. HMGI(Y) gene expression in the selected population diagnosed with colorectal
cancer: comparison with some histological typing, grading and clinical staging.
Pathology Res & Practice 199, 641-646, 2003
Former participation in an FP European project? NO
Research topics
• HEALTH-2007-1.2-6: High throughput molecular diagnostics in individual patients for genetic diseases
with heterogeneous clinical presentation.
• HEALTH-2007-2.4.1-10: Role of inflammation in tumour initiation and progression.
• HEALTH-2007-2.4.1-11: Epidemiology of gene-environment interactions involved in carcinogenesis.
• HEALTH-2007-2.4.1-9: Innovative combination clinical trials for multimodal cancer therapy.
• HEALTH-2007-3.1-5: Better use of medicines.
Expertise/commitment offered
Keywords
specifying the
expertise:
gene expression, gene polymorphism, apoptosis, cytotoxicity, new anticancer
agents, PCR, real-time PCR, RFLP, sequencing, immumoassays
Description of the
expertise:
Gene expression and gene polymorphism evaluation in cancer diagnosis and
prognosis.
Estimation of antiproliferative and proapototic action of new potential anticancer
agents.
Commitment
offered
Research
Expectations
Term
commitment:
Medium (1 to 3 years)
Expected results
for your
organisation:
Our goal is to find cooperants in order to apply for 7FP grants.